Citius Oncology (CTOR) Stock Analysis
NASDAQHealthcareMedical - Pharmaceuticals
What Citius Oncology does
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
Key metrics
ETFs linked to CTOR
Broad-market and Healthcare sector ETFs an investor holding Citius Oncology is often also exposed to. Open an ETF page to see its actual top holdings.
PortView Portfolio Insights
PortView analyzes how CTOR fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze CTOR in PortView →Similar companies
Frequently asked questions
- What is the ticker symbol for Citius Oncology?
- Citius Oncology trades under the ticker CTOR on NASDAQ.
- Which exchange is CTOR listed on?
- CTOR is listed on NASDAQ.
- What sector does Citius Oncology operate in?
- Citius Oncology is classified in the Healthcare sector (Medical - Pharmaceuticals industry).
- How can PortView help analyze CTOR in a portfolio?
- PortView shows CTOR's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.